Colorectal Cancer Clinical Trial
— METASYNCOfficial title:
Prospective Randomized Study Comparing the Morbidity and Mortality After Liver Resection for Synchronous Colorectal Cancer Metastases When Performed Either During or 12 to 14 Weeks After the Primary Resection
Verified date | March 2019 |
Source | Rennes University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The surgical strategy for the treatment of synchronous colorectal cancer liver metastases has not still been defined. The purpose of this study is to compare two treatment strategies in which liver resection is performed either during, or 12 to 14 weeks after the primary resection. Endpoints include the rate of severe complications and survival.
Status | Terminated |
Enrollment | 105 |
Est. completion date | December 11, 2017 |
Est. primary completion date | December 11, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male and female adults over 18 years old - At least one adenocarcinoma of colon and/or rectum, histologically proven. - No local complication at the time of surgery (no occlusion, no sub-occlusion, no massive hemorrhage, no abscesses or local invasion) - At least one hepatic metastasis which R0 resection is possible through a conventional simple resection - Informed written consent. Non inclusion criteria: - Heart, Respiratory or Renal failure - Physical or psychological dependence - Chronic liver disease - Extra-hepatic metastases Exclusion Criteria (at time of surgery) - Localized or diffuse peritoneal carcinomatosis - Non resectable lymph node metastases - Colorectal or hepatic tumour extension towards abdominal wall and/or adjacent organ making liver R0 resection impossible immediately - Other hepatic lesions diagnosed with ultrasound making liver R0 resection impossible immediately |
Country | Name | City | State |
---|---|---|---|
France | Chirurgie générale viscérale et digestive - Hôpital Nord | Amiens | |
France | Service de Chirurgie viscérale, digestive et cancérologie - Hôpital Jean Mingoz | Besancon | |
France | Chirurgie digestive, thoracique et cancérologie | Dijon | |
France | Département de Chirurgie - CRLCC Léon Bérard | Lyon | |
France | Clinique Chirurgicale A - Hôtel Dieu | Nantes | |
France | Clinique Chirurgicale I - Hôpital Nord | Nantes | |
France | Centre de Chirurgie et Réanimation Digestives - Hôpital Saint Antoine | Paris | |
France | Service de Chirurgie hépato-biliaire et Transplantation Hépatique- Paris Saint Antoine | Paris | |
France | Service de Chirurgie - Hôpital Jean Bernard | Poitiers | |
France | Département de Chirurgie Viscérale - Hôpital Pontchaillou | Rennes | |
France | Service d'Oncologie Digestive- CRLCC Eugène Marquis | Rennes | |
France | Centre de Chirurgie Viscérale et de Transplantation - CHU de Hautepierre | Strasbourg | |
France | Chirurgie Viscérale Digestive - CH Chubert | Vannes | |
France | Centre Hépato-biliaire - Hôpital Paul Brousse | Villejuif |
Lead Sponsor | Collaborator |
---|---|
Rennes University Hospital | Ministry of Health, France |
France,
Martin R, Paty P, Fong Y, Grace A, Cohen A, DeMatteo R, Jarnagin W, Blumgart L. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2. — View Citation
Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D. Simultaneous resection of colorectal primary tumour and synchronous liver metastases. Br J Surg. 2003 Aug;90(8):956-62. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of patients with at least one postoperative severe complication within 60 days after each surgery | 60 days after each surgery | ||
Secondary | Death rate during hospitalization or within 60 days after each surgery | 60 days after each surgery | ||
Secondary | Rate and number of severe general, digestive or hepatic complications | 2 years after the first surgery | ||
Secondary | Rate of unachieved hepatic resection | Day of the hepatic surgery | ||
Secondary | Global survival distribution and 2 years global survival rate | 2 years after the first surgery | ||
Secondary | Recurrence-free survival distribution and 2 years recurrence-free survival rate | 2 years | ||
Secondary | Two years recurrence rate | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |